News stories about AVEO Pharmaceuticals (NASDAQ:AVEO) have been trending somewhat positive this week, according to Alpha One. Alpha One, a subsidiary of Accern, rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AVEO Pharmaceuticals earned a news impact score of 0.04 on Alpha One’s scale. Alpha One also gave media coverage about the biopharmaceutical company an impact score of 75 out of 100, indicating that recent media coverage is likely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have effected AlphaOne Sentiment’s analysis:
- AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) vs. Celsion Corporation (NASDAQ:CLSN) Heady Investors are Taking a … – Stock Press Daily (stockpressdaily.com)
- Company Focus on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) – Lenox Ledger (lenoxledger.com)
- AVEO Oncology Announces Completion of a CHMP Oral Explanation for Tivozanib as a Treatment of First-Line Renal Cell Carcinoma (finance.yahoo.com)
- CFO Moves: AVEO Pharmaceuticals, Community Health Systems (blogs.wsj.com)
- Immune Design Corp : Investor Network: Immune Design Corp. to Host Earnings Call (4-traders.com)
A number of research analysts have issued reports on AVEO shares. FBR & Co restated an “outperform” rating and issued a $3.00 target price on shares of AVEO Pharmaceuticals in a report on Monday, April 17th. Zacks Investment Research lowered shares of AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 27th.
Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) opened at 0.725 on Friday. AVEO Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $1.15. The firm has a 50-day moving average of $0.60 and a 200 day moving average of $0.66. The firm’s market cap is $80.01 million.
AVEO Pharmaceuticals (NASDAQ:AVEO) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.12). AVEO Pharmaceuticals had a negative return on equity of 286.18% and a negative net margin of 465.54%. The company had revenue of $2.53 million during the quarter. On average, equities research analysts anticipate that AVEO Pharmaceuticals will post ($0.41) EPS for the current fiscal year.
In other news, major shareholder Equity Opportunities Iv Growth purchased 6,000,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 28th. The stock was acquired at an average cost of $0.50 per share, with a total value of $3,000,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 5.10% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “AVEO Pharmaceuticals (AVEO) Receives Daily Media Sentiment Score of 0.04” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://sportsperspectives.com/2017/05/20/aveo-pharmaceuticals-aveo-receives-daily-news-sentiment-score-of-0-04-updated-updated.html.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.